CORDIS
EU research results

CORDIS

English EN

Early clinical development of a live, attenuated combination vaccine against Shigella and ETEC diarrhoea

Project information

Grant agreement ID: 815568

Status

Ongoing project

  • Start date

    1 September 2019

  • End date

    31 August 2024

Funded under:

H2020-EU.3.1.3.

Coordinated by:

EUROPEAN VACCINE INITIATIVE EWIV

Germany

Project description

English EN

A pioneering vaccine for diarrhoea may accomplish what predecessors could not

Diarrhoea is typically a non-threatening nuisance in western civilisations but it is a killer in developing countries, particularly for children under five years of age. In cases where children do survive, malnourishment due to poverty is augmented by dehydration and severe undernutrition as a result of infection. This can have long-term effects on physical and cognitive development. SHIGETECVAX is developing a novel oral vaccine against two closely related bacteria that are leading causes of diarrhoea. Based on antigens not targeted in previous vaccines, it is much safer, enabling higher doses. Potentially more effective against both pathogens, this vaccine could save millions of lives.

Coordinator

EUROPEAN VACCINE INITIATIVE EWIV

Address

Vossstrasse 2 Geb 4040
69115 Heidelberg

Germany

Activity type

Research Organisations

EU Contribution

€ 359 755

Participants (4)

EVELIQURE BIOTECHNOLOGIES GMBH

Austria

EU Contribution

€ 5 024 401,62

GOETEBORGS UNIVERSITET

Sweden

EU Contribution

€ 749 842,50

INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH BANGLADESH

Bangladesh

EU Contribution

€ 1 924 713,27

PATH

United States

EU Contribution

€ 545 277,54

Project information

Grant agreement ID: 815568

Status

Ongoing project

  • Start date

    1 September 2019

  • End date

    31 August 2024

Funded under:

H2020-EU.3.1.3.

Coordinated by:

EUROPEAN VACCINE INITIATIVE EWIV

Germany